Home > Remogliflozin etabonate

molecules of the month

Remogliflozin etabonate

SGLT1-sparing oral SGLT2 inhibitor prodrug

launched in India for diabetes, 100 mg BID

from mouse urine drug metabolite and opt.

Bioorg. Med. Chem., Jan. 22, 2021

Kissei Pharma / Toho University, JP

Recent Article Upgrade Membership to Download Slide Deck

Recent Article Upgrade Membership to Download Slide Deck

1 min read

The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes. Interestingly, the lead for this drug was a metabolite identified from mouse urine after treatment with a Wyeth-Ayerst antihyperglycemic agent of previously unknown mechanism.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

Remogliflozin etabonate

request a trial

already a member? log in: